Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03599362 · ClinicalTrials.gov registry record · Phase 2
Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03599362: Clinical Trial Phase 2 study, sponsored by NYU Langone Health.
NCT03599362 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03599362, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
A multi-institutional, single arm phase II study of nivolumab, cabiralizumab and stereotactic body radiotherapy (SBRT) in patients with LAUPC. The purpose of this study is to determine the safety and tolerability of combined cabiralizumab, nivolumab and radiotherapy in the treatment of locally advanced pancreatic cancer. Investigators will also estimate the surgical resection rate following treatment with combined cabiralizumab, nivolumab and radiotherapy in subjects with locally advanced unresectable pancreatic cancer.
Primary Outcome
Measure of safety of combined cabiralizumab, nivolumab and radiotherapy in the treatment of locally advanced pancreatic cancer measured by unacceptable toxicity, which includes: * Grade 3 fatigue lasting \> 2 Weeks * Grade 3 Nausea lasting \> 7 days despite maximal medical management * Grade 3 or more anorexia * Grade 3 or more vomiting * Grade 3 or more diarrhea * Grade 3 or more pancreatitis * Grade 3 abdominal pain * Grade 3 or more radiation dermatitis * Grade 3 or more GI hemorrhage * Grad
Interventions
- RADIATION Stereotactic Body Radiotherapy (SBRT)
- DRUG Nivolumab + Cabiralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2020-06-15 |
| Phase | Phase 2 |
Why NCT03599362 stopped before completion
NCT03599362 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Stereotactic Body Radiotherapy (SBRT) is the first listed.
NCT03599362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03599362 about?
NCT03599362 is a clinical study titled "Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer". A multi-institutional, single arm phase II study of nivolumab, cabiralizumab and stereotactic body radiotherapy (SBRT) in patients with LAUPC. The purpose of this study is to determine the safety and tolerability of combined cabiralizumab, nivolumab and radiotherapy in the treatment of locally advan...
What is the current status of trial NCT03599362?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2018-07-31. Estimated completion is 2020-06-15.
What interventions are being tested in trial NCT03599362?
The interventions under investigation include: Stereotactic Body Radiotherapy (SBRT) (RADIATION), Nivolumab + Cabiralizumab (DRUG).
Who is sponsoring clinical trial NCT03599362?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03599362's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI